Exelixis stock
Price history
+60.34% over the period1 year: from $42.42 (November 17, 2025) to $68.02 (November 17, 2026), +60.34%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | $68.02 |
| October 30, 2026 | $69.39 |
| September 30, 2026 | $58.41 |
| August 31, 2026 | $54.64 |
| July 31, 2026 | $53.03 |
| June 30, 2026 | $54.41 |
| May 29, 2026 | $50.48 |
| April 30, 2026 | $44.46 |
| March 31, 2026 | $42.89 |
| February 27, 2026 | $44.06 |
| January 30, 2026 | $41.36 |
| December 31, 2025 | $43.83 |
| November 28, 2025 | $44.17 |
| November 17, 2025 | $42.42 |
At a glance
The company
Develops and commercializes oncology medicines for difficult-to-treat cancers, including CABOMETYX and COTELLIC, in the United States
Latest results
Quarter to September 30, 2026 · EPS $0.94 (estimate $0.87)
TickerLandia's take on Exelixis
- Priced as usual relative to earnings: P/E on the latest fiscal year 24 vs a median of 25 over its last 9 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 20 vs 50 (−60%) in a group of 8.
- Strong point: Market momentum (95/100 in its group). Weak point: Growth (41/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−7.04% from the 52-week high
Analysts · 17 analysts
Average target$61.57−10.11% vs. price
Buy 6 · Hold 10 · Sell 1 · Buy
TickerLandia Fingerprint: Exelixis
Compared with similar companies: very strong momentum and very high profitability.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricelow36
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 20.1 24 EV/EBITDA 15.2 25 Price/book 8.95 72 Forward P/E 15.7 23 Price/sales 6.56 34 Profitabilityvery high89
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 96.3% 88 Net margin 35.5% 86 Operating margin 40.2% 86 ROE 44.3% 88 ROA 23.5% 96 Earnings stabilityhigh76
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 11.5% 68 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 84 Growthaverage41
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +12.93% 34 Revenue growth (year over year) +10.20% 28 Earnings growth (year over year) +23.20% 60 Financial strengthaverage50
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.09 54 Current ratio 3.21 46 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery strong95
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +36.72% 99 Relative strength (6 months) +36.50% 91 1-year return +61.48% 93 Distance from 200-day average +30.47% 98 Risklow31
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 12.6% 4 Volatility (60 days) 29.9% 38 Beta (1 year) 0.67 50
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Exelixis is priced as in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), Exelixis's P/E today is 24.5, in line with the median of its last 9 fiscal years (25.4; between 8.80 and 62.0 from 2017 to 2025). Exelixis's P/E (trailing 12 months): 20.1, −60% against the median of a group of 8 similar companies (49.6).
Compared with 8 similar companies
| Metric | Exelixis | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 20.1 | Middle | |
| Forward P/E | 15.7 | Middle | |
| Operating margin | 40.2% | High | |
| ROE | 44.3% | Middle | |
| Debt/equity | 0.09 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Exelixis. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$658.7M
Latest quarter · Q3 2026
Net income
$218.1M
Latest quarter · Q3 2026
Quarterly net margin
33.1%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $16.37B
- P/E
- 20.1
- EPS
- $3.34
- Volume
- 2.68M
- Daily trading
- €182.55M
- Dividend yield
- 0.00%
How Exelixis is changing
All resultsRevenue grew 18.6% a year on average over the last 5 years
Operating margin rose from 12.5% to 37.6%
Profits turn into cash: free cash flow equal to 122% of net income
Returns
Exelixis returns
$1,000 invested in Exelixis 5 years ago, on November 17, 2021, would be worth $3,804 today: +280.40% in total, +30.64% per year. This is the price return only: dividends are excluded.
| Period | Exelixis | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +8.51% | −3.17% | $1,085 |
| 6 months | +36.64% | +0.11% | $1,366 |
| Year to date | +55.18% | +8.34% | $1,552 |
| 1 year | +60.34% | +11.15% | $1,603 |
| 3 years | +221.89% | +64.30% | $3,219 |
| 5 years | +280.40% | +58.18% | $3,804 |
| 10 years | +306.06% | +239.10% | $4,061 |
Over the last 6 months it has done better than 75% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Exelixis: technical analysis
Exelixis is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 5.8% below its all-time closing high ($72.75, November 4, 2026).
- Trend
- Upward
- RSI (14 sessions)
- 56
- Between 30 and 70
- vs 200-session average
- +30.47%
Support and resistance
Price areas where Exelixis has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price$68.50
- Support$59.44−13.23%2 touches, last on September 18, 2026
- Support$56.93−16.89%5 touches, last on October 6, 2026
- Support$54.01−21.16%5 touches, last on September 11, 2026
Volatility and risk
Over the last year it has moved less than the S&P 500.
- Beta (1 year) vs S&P 500
- 0.67
- Volatility (60 sessions, annualised)
- 29.9%
- Largest fall in the last year
- −12.59%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Exelixis: seasonality
Average monthly price change over 27 years
Over the last 27 years, the strongest month for Exelixis has been November: +6.31% on average, positive in 16 years out of 26. The weakest has been September: −3.34% on average, positive in 13 years out of 27.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +1.44% | +0.84% | 13 of 26 |
| February | +2.30% | −0.75% | 13 of 26 |
| March | −1.13% | −0.27% | 13 of 26 |
| April | +5.28% | +3.51% | 15 of 26 |
| May | +0.85% | −0.36% | 13 of 27 |
| June | +2.83% | +3.60% | 16 of 27 |
| July | +3.96% | +0.48% | 14 of 27 |
| August | −0.80% | −0.53% | 13 of 27 |
| September | −3.34% | −0.31% | 13 of 27 |
| October | +0.12% | +1.75% | 15 of 27 |
| November | +6.31% | +3.77% | 16 of 26 |
| December | +5.20% | +4.58% | 16 of 26 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Exelixis and its competitors
Exelixis, Inc. is based in Alameda, California, and was founded in 1994. It is an oncology company focused on discovering, developing and commercializing medicines for difficult-to-treat cancers, with its revenue concentrated in the United States. Its products include CABOMETYX tablets for advanced renal cell carcinoma after prior anti-angiogenic therapy, COMETRIQ capsules for progressive and metastatic medullary thyroid cancer, COTELLIC for certain forms of advanced melanoma in combination, and MINNEBRO, offered for hypertension in Japan. Its pipeline includes zanzalintinib, XL309, XB010, XB628 and XB371.
- Headquarters
- Alameda, United States
- Employees
- 1,077
- Founded
- 1994
- Chief executive
- Michael Morrissey
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| ExelixisEXEL | $16.37B | 40.2% | 20.1 | +36.64% |
| Jazz PharmaceuticalsJAZZ | $15.5B | 27.4% | 71.5 | +5.22% |
| BridgeBio PharmaBBIO | $15.25B | -37.3% | — | +16.13% |
| Ascendis PharmaASND | $18.06B | 30.9% | 18.1 | +12.76% |
| Halozyme TherapeuticsHALO | $14.67B | 56.8% | 38.3 | +42.98% |
| BioNTechBNTX | $21.22B | -55.4% | — | −5.24% |
Same industry or related industries, similar size. Compare Exelixis with its competitors · Full profile
